Tscan Therapeutics Inc (NASDAQ:TCRX) currently has a daily average trading volume of 577.92K but it saw 272654 shares traded in last market. With a market cap of 82.62M USD, the company’s current market price of $1.46 came falling about -5.19 while comparing to the previous closing price of $1.54. In past 52 weeks, the stock remained buoying in the range of price level as high as $7.89 and as low as $1.02. In the recent trading on the day, stock has struck highest price mark of $1.46 while lowest mark touched by it was $1.6.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the BTIG Research which initiated the stock as “Buy” in its note to investors issued on May 16, 2024, recommending a price target of $12 for it. Wedbush also issued its recommendations for the stock as it initiated the price target for the stock is $8.
Over the week, TCRX’s stock price is moving -8.75% down while it is 17.74% when we observe its performance for the past one month. Year-to-date it is -51.97% down and over the past year, the stock is showing a downside performance of -82.62%.
The company is expected to be releasing its next quarterly report on 2025-May-06, for which analysts forecasted an EPS of -0.32 while estimate for next year EPS is -1.23. In next quarter, company is expected to be making quarterly sales of $1.3M as analysts are expecting the sales for current fiscal year at $5.88M and seeing the company making $7.94M in sales next year. Moreover, analysts are in estimates of $1.3M for current-quarter revenue.
Currently, Tscan Therapeutics Inc’s total number of outstanding shares is 52.31M. Company’s return on investment (ROI) stands at -43.50% and return on equity (ROE) at -78.93%. Stock’s beta reads 0.98. Stock has a price to book (P/B) ratio of 0.39 while price to sale or P/S ratio amounts to 18.69. Its return on asset (ROA) is -45.85% on average.
